SPDR® S&P Pharmaceuticals ETF’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze. The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.  

 The strategy’s management team earns an Above Average People Pillar rating. The strategy earns an Average Process Pillar rating. Independent of the rating, analysis of the strategy's portfolio shows it has maintained an overweight liquidity exposure and has a substantial underweight in quality exposure compared with category peers. High liquidity exposure is attributed to stocks with a high trading volume, lending managers more flexibility. And a low quality exposure is rooted in stocks with higher financial leverage and lower profitability. The strategy's parent organization earns the firm an Above Average Parent Pillar rating. People Pillar and Parent Pillar ratings for this strategy are indirectly assigned by a Morningstar analyst rather than algorithmically derived. Please see the notes following each pillar section for more details. The details of assigning methods can be found in each pillar section.

Analyst Rating

Intra-Cellular Therapies

Merck

Catalent

Eli Lilly

Perrigo

Organon & Co

Axsome Therapeutics

Pfizer

Jazz Pharmaceuticals

Royalty Pharma

Morningstar's evaluation of this security's process aims to determine the likelihood that it will outperform its Morningstar Category index on a risk-adjusted basis over the long term. SPDR® S&P Pharmaceuticals ETF earns an Average Process Pillar rating. The primary contributor to the rating is that this fund tracks an index. Historical data, like Morningstar's Active/Passive Barometer, finds that passively managed funds have generally outperformed their active counterparts, especially over longer time horizons. The fund's concentrated portfolio, with its top 10 holdings accounting for 50% of assets, strengthens the process. High-conviction picks court the risk of blowing up, but can also drive outperformance. Lastly, the process is limited by the fund's unremarkable long-term risk-adjusted performance. This can be seen in its five-year alpha calculated relative to the category index, which suggests that the process has struggled over that period.

The investment strategy as stated in the fund's prospectus is:  The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index.  In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, and of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). 

 The portfolio has allocations in its top two sectors, healthcare and financial services, that are similar to the category. The sectors with low exposure compared to category peers are basic materials and technology; however, the allocations are similar to the category. The portfolio is composed of 37 holdings and is relatively concentrated. In particular, 49.6% of the fund’s assets are housed within the top 10 holdings, compared with the typical peer's 38.7%. And finally, in terms of portfolio turnover, looking at year-over-year movements, 53% of the fund's holdings have turned over, whether through increasing, decreasing, or changing a position.

Average

Process

SPDR® S&P Pharmaceuticals ETF's strong team drives the strategy's Above Average People Pillar rating. There are two managers listed on the fund: Karl Schneider, Keith Richardson. The team is well equipped, with an average of 17 years of portfolio management experience. Together, they manage a total of six strategies, with solid long-term prospects. The strategies average a Silver asset-weighted Morningstar Medalist Rating, indicating a position to deliver positive alpha relative to the category median in aggregate.  

 Note: This People Pillar rating is indirectly assigned by an analyst. Morningstar analysts evaluate the People Pillar for passive products at the brand level and may also differentiate by asset class. There is at least one other passive strategy at the firm that is covered by a Morningstar analyst, so the People Pillar rating of the fund is inherited from the rating that the Morningstar analyst assigned to investment vehicles under the same brand name.

Above Average

People

State Street Global Advisors is under new leadership but continues to move along the positive trajectory established by former leaders. SSGA maintains its Above Average Parent Pillar rating.
Cyrus Taraporevala, who oversaw much of SSGA’s recent transformation, retired from the CEO position in December 2022 and passed the baton to his successor, Yie-Hsin Hung. She inherited a business that’s become more disciplined with its fund lineup. Fees have come down, while product development remains focused on fixed-income and sustainability funds, and many of SSGA’s launches have echoed that intention.
The seeds that SSGA planted over the past several years have been bearing fruit. It built out a low-cost series of portfolio building-block ETFs in the U.S. bearing the “SPDR Portfolio” branding. SSGA launched these later than its industry rivals, so they aren’t as large. But they’re competitive, with solid management and low fees, which helped them consistently take in new money over the past several years.
SSGA continued to overhaul its ETF business in Europe with most of its recent fixed-income and sustainability fund launches. Many of these funds track indexes and charge relatively low fees. With operations in the U.S. and Europe standing on a firm foundation, SSGA will put more focus on its Asia-Pacific business—the smallest regional segment of its business.

Parent

SPDR S&P Pharmaceuticals ETF

XPH tracks an equal-weighted index of US pharmaceutical companies.

The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceuticals Select Industry Index and provides a cost-effective way to gain exposure to the sector. The top holdings of XPH include Axsome Therapeutics, Eli Lilly, Merck & Co., Pfizer, and Jazz Pharmaceuticals, offering diversification and potential for growth within the pharmaceutical sector.

XPH: A More Balanced Way To Get Exposure To Pharmaceuticals

Making its debut on 06/19/2006, smart beta exchange traded fund SPDR S&P Pharmaceuticals ETF (XPH) provides investors broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Bristol-Myers

Nasdaq Pharm Shs Nasdaq Pharmaceuticals

iShares U.S. Pharmaceuticals ETF

Johnson & Johnson

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q3 Earnings

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

iShares US Infrastructure ETF

Global X U.S. Infrastructure Development ETF

SPDR S&P Health Care Services ETF

Value-focused investing comes to rescue if high-growth sectors fail for some reasons.

Cautious on Big Tech & AI? Try These Value-Focused Sector ETFs

XPH's consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 2030, and narrow revenue stream expected from orphan drugs will impact the pharmaceutical industry. Revlimid, Januvia/Janumet, Reyvow, Bedaquiline, Keytruda, Opdivo, Eliquis, Ibrance, Stelara, Trulicity - all drugs are going to become off-patent by 2030.

XPH: Non-Diversified U.S.-Based Large-Cap Pharma ETF Isn't Very Attractive

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.

Pharma ETFs Gain Post Q1 Earnings

XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector. Patent expirations are a major headwind affecting many companies in the industry.

XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

A Look at Pharma ETFs Post Q4 Earnings

A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.

Will 2023 be the year that pharma M&A makes a comeback?

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares Global Healthcare ETF

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Novo Nordisk

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

ALPS Medical Breakthroughs ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Amgen

Horizon Pharma

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

XPH invests in U.S. pharmaceuticals stocks. The fund is concentrated in 44 holdings.

XPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically Unattractive

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025.

What The Inflation Reduction Act Means For Drug Prices

Chemocentryx

Global Blood Therapeutics

Seagen

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

Some health care sector ETFs have exposure to companies like Johnson & Johnson, Pfizer, UnitedHealth

Pharma market investments: How ETFs help you dabble in the sector at a modest price

Global X SuperDividend US ETF

DIA and XPH saw massive trading volume in yesterday session.

2 ETFs to Watch for Outsized Volume on Dividend and Pharma

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q1 Earnings

GlaxoSmithKline

Sanofi

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Solid Q4 Earnings Fail to Impress Pharma ETFs

Gilead Sciences

Novocure

United Therapeutics

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

News for SPDR S&P Pharmaceuticals ETF ETF (XPH)